Meropenemβ-lactam antibiotic of the carbapenem subclass CAS# 96036-03-2 |
- Biapenem
Catalog No.:BCC1071
CAS No.:120410-24-4
- (S)-Tedizolid
Catalog No.:BCC1294
CAS No.:1431699-67-0
- Aprepitant
Catalog No.:BCC1101
CAS No.:170729-80-3
- Doripenem Hydrate
Catalog No.:BCC1160
CAS No.:364622-82-2
- Toltrazuril sulfone
Catalog No.:BCC2008
CAS No.:69004-04-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 96036-03-2 | SDF | Download SDF |
| PubChem ID | 64778 | Appearance | Powder |
| Formula | C17H25N3O5S | M.Wt | 383.46 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | (4R,5S,6S)-3-[(2S,5S)-5-(dimethylcarbamoyl)pyrrolidin-2-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | ||
| SMILES | CC1C2C(C(=O)N2C(=C1SC3CCC(N3)C(=O)N(C)C)C(=O)O)C(C)O | ||
| Standard InChIKey | FSTGLKRHSQANLP-PQTSNVLCSA-N | ||
| Standard InChI | InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-10-6-5-9(18-10)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Meropenem is a carbapenem antibiotic, which displaying a broad spectrum of antibacterial activity.
Target: Antibacterial
Meropenem, a new parenteral carbapenem demonstrated increased activity as compared to imipenem against 336 strains of Neisseria gonorrhoeae, 119 strains of Haemophilus influenzae, and 110 strains of H. Ceftriaxone and ciprofloxacin demonstrated activity superior to that of both carbapenems while the activity of ceftazidime was similar to that of meropenem [1]. Meropenem, like imipenem and various experimental penems, may overcome the resistance problems presented by Class I beta-lactamases [2]. MEROPENEM was rapidly penetrated to the pleural effusion and was retained for a more prolonged time in the pleural effusion than in the blood of patients with accumulated pleural effusion, and it suggested the usefulness of MEROPENEM in antibacterial therapy for patients with pleurisy causing accumulation of pleural effusion [3].
Clinical indications: Appendicitis; Bacterial infection; Bacterial meningitis; Bacterial pneumonia; Bacterial respiratory tract infection; Bacterial skin infection; Bacterial urinary tract infection; Bacteroides fragilis infection; Bacteroides infection; Bacteroides thetaiotaomicron infection; Complicated skin and skin structure infection
FDA Approved Date: July 1996
Toxicity: In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities. References: | |||||
Meropenem Dilution Calculator
Meropenem Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6078 mL | 13.0392 mL | 26.0783 mL | 52.1567 mL | 65.1958 mL |
| 5 mM | 0.5216 mL | 2.6078 mL | 5.2157 mL | 10.4313 mL | 13.0392 mL |
| 10 mM | 0.2608 mL | 1.3039 mL | 2.6078 mL | 5.2157 mL | 6.5196 mL |
| 50 mM | 0.0522 mL | 0.2608 mL | 0.5216 mL | 1.0431 mL | 1.3039 mL |
| 100 mM | 0.0261 mL | 0.1304 mL | 0.2608 mL | 0.5216 mL | 0.652 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Meropenem is a β-lactam antibiotic of the carbapenem subclass that has been shown to inhibit penicillinase-negative, -positive and methicillin-susceptible staphylococci. This compound demonstrates the ability to also affect strains of 11 species of strept
- Vortioxetine (Lu AA21004) HBr
Catalog No.:BCC1213
CAS No.:960203-27-4
- SD 1008
Catalog No.:BCC2442
CAS No.:960201-81-4
- 2-hexyl-4-Pentynoic Acid
Catalog No.:BCC6480
CAS No.:96017-59-3
- Mepivacaine
Catalog No.:BCC9020
CAS No.:96-88-8
- Aminothiazole
Catalog No.:BCC4623
CAS No.:96-50-4
- Guajadial
Catalog No.:BCN4509
CAS No.:959860-49-2
- CH5138303
Catalog No.:BCC5364
CAS No.:959763-06-5
- Guggulsterone Z
Catalog No.:BCN3793
CAS No.:95975-55-6
- TC-E 5005
Catalog No.:BCC6227
CAS No.:959705-64-7
- 5,7,4-Trihydroxy-3,6-dimethoxy-3-prenylflavone
Catalog No.:BCN1297
CAS No.:959421-20-6
- 4-Hydroxyalternariol 9-methyl ether
Catalog No.:BCN7389
CAS No.:959417-17-5
- PF 750
Catalog No.:BCC7641
CAS No.:959151-50-9
- ONX-0914 (PR-957)
Catalog No.:BCC2095
CAS No.:960374-59-8
- Jatrorrhizine Hydrochloride
Catalog No.:BCC8193
CAS No.:960383-96-4
- ent-17-Hydroxykauran-3-one
Catalog No.:BCN4510
CAS No.:960589-81-5
- Massoniresinol
Catalog No.:BCN4511
CAS No.:96087-10-4
- Stylopine hydrochloride
Catalog No.:BCN6964
CAS No.:96087-21-7
- 2'-Deoxyguanosine
Catalog No.:BCC5433
CAS No.:961-07-9
- Isoliquiritigenin
Catalog No.:BCN4512
CAS No.:961-29-5
- MPEP
Catalog No.:BCC4594
CAS No.:96206-92-7
- Epidermal Growth Factor Receptor Peptide (985-996)
Catalog No.:BCC1014
CAS No.:96249-43-3
- Methyl 8-hydroxy-3-(2-methoxy-2-oxoethyl)-6-methyl-9-oxo-9H-furo[3,4-b]chromene-1-carboxylate
Catalog No.:BCN7465
CAS No.:96287-41-1
- Androst-2-en-17-one
Catalog No.:BCC8821
CAS No.:963-75-7
- Huzhangoside D
Catalog No.:BCN2527
CAS No.:96315-53-6
Meropenem, levofloxacin and linezolid in human plasma of critical care patients: A fast semi-automated micro-extraction by packed sorbent UHPLC-PDA method for their simultaneous determination.[Pubmed:28371721]
J Pharm Biomed Anal. 2017 Jun 5;140:266-273.
An ultra high-performance liquid chromatographic (UHPLC) method with PDA detection was developed and validated for the simultaneous quantification of Meropenem, linezolid, and levofloxacin in human plasma and applied in human plasma of critical care patients. A semi-automated microextraction by packed sorbent (MEPS) for sample preparation was used. All parameters in the extraction step (pH, sample volume, sample dilution and number of aspiration - ejection cycles) and in the desorption step (percentage of acetonitrile in the solvent of elution and number of aspirations of elution solvent through the device) were statistically significant when the recovery was used as response. The method showed good linearity with correlation coefficients, r(2)>0.9991 for the three drugs, as well as high precision (RSD%<10.83% in each case). Accuracy ranged from -7.8% to +6.7%. The limit of quantification of the three drugs was established at 0.01mug/mL for linezolid and levofloxacin and 0.02mug/mL for Meropenem. Linezolid, Meropenem, levofloxacin and the internal standard were extracted from human plasma with a mean recovery ranged from 92.4% to 97.4%. During validation, the concentration of Meropenem, linezolid and levofloxacin was found to be stable after 3 freeze-thaw cycles and for at least 24h after extraction. This method will be subsequently used to quantify the drugs in patients to establish if the dosage regimen given is sufficient to eradicate the infection at the target site.
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.[Pubmed:28369424]
J Antimicrob Chemother. 2017 Jul 1;72(7):1981-1984.
Objectives and methods: We evaluated the in vitro activity of different antimicrobial combinations with and without colistin against 39 carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains (colistin + Meropenem/doripenem, colistin + tigecycline, colistin + rifampicin, gentamicin + Meropenem, gentamicin + tigecycline and the double-carbapenem regimen Meropenem + ertapenem) using the chequerboard method. The triple combination colistin + Meropenem + tigecycline was also tested. In addition, killing studies were performed for Meropenem + ertapenem. Results: Gentamicin-based combinations showed a high level of synergy. Meropenem + ertapenem was synergic in 12/39 (30.7%) of the strains, whereas based on killing studies 1 x MIC Meropenem + 1 x MIC ertapenem and 2 x MIC Meropenem + 1 x MIC ertapenem combinations were bactericidal and synergic at 24 h [mean area under the bactericidal curve (AUBC) 54.9+/-26.1 and 44.2+/-15.3 compared with 1 x MIC Meropenem (134.5+/-40.1) and 2 x MIC Meropenem (126.4+/-5.4), respectively, P < 0.0001]. When the results were stratified according to Meropenem MIC, we found that the degree of synergy significantly increased for isolates with lower Meropenem (and not ertapenem) MICs, up to an MIC of 128 mg/L. Among colistin-containing combinations, synergy was observed in 18/39 (46.1%), 33/34 (97%), 24/39 (61.5%) and 17/39 (43.5%) of the strains for colistin + Meropenem, colistin + rifampicin, colistin + tigecycline and colistin + doripenem, respectively, including colistin-resistant strains. Colistin + Meropenem + tigecycline at subinhibitory concentrations resulted in the absence of growth of 37/39 strains (94.8%). Conclusions: Our in vitro data suggest that colistin might be a valid therapeutic option against CR-Kp, even in the presence of colistin resistance, whereas the double-carbapenem regimen represents a viable option when colistin is not recommended, especially if the Meropenem MIC is Meropenem MIC evaluation should always be performed in the case of CR-Kp infections.
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.[Pubmed:28363526]
Int J Antimicrob Agents. 2017 May;49(5):579-588.
Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-beta-lactam beta-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam plus metronidazole compared with Meropenem in patients with complicated intra-abdominal infection (cIAI) in Asian countries. Subjects aged 18-90 years and hospitalised with cIAI requiring surgical intervention were randomised 1:1 to receive every 8 h either: ceftazidime/avibactam (2000/500 mg, 2-h infusion) followed by metronidazole (500 mg, 60-min infusion); or Meropenem (1000 mg, 30-min infusion). Non-inferiority of ceftazidime/avibactam plus metronidazole to Meropenem was concluded if the lower limit of the 95% confidence interval (CI) for the between-group difference in clinical cure rate was greater than -12.5% at the test-of-cure (TOC) visit (28-35 days after randomisation) in the clinically evaluable (CE) population. Safety was also evaluated. Of 441 subjects randomised, 432 received at least one dose of study medication (ceftazidime/avibactam plus metronidazole, n = 215; Meropenem, n = 217). In the CE population at the TOC visit, non-inferiority of ceftazidime/avibactam plus metronidazole to Meropenem was demonstrated, with clinical cure reported for 93.8% (166/177) and 94.0% (173/184) of subjects, respectively (between-group difference, -0.2, 95% CI -5.53 to 4.97). The clinical cure rate with ceftazidime/avibactam plus metronidazole was comparable in subjects with ceftazidime-non-susceptible and ceftazidime-susceptible isolates (95.7% vs. 92.1%, respectively). Adverse events were similar between the study groups. Ceftazidime/avibactam plus metronidazole was non-inferior to Meropenem in the treatment of cIAIs in Asian populations and was effective against ceftazidime-non-susceptible pathogens. No new safety concerns were identified.
